Lamivudine, usually shortened to 3TC, is a nucleoside reverse transcriptase inhibitor that has been in use since the mid-1990s and remains part of current first-line regimens. Few medicines in any field are as well tolerated.
What kind of drug is it?
A nucleoside analogue, from the oldest class of HIV medicines. It is a synthetic version of cytidine, one of the four natural building blocks of DNA, modified so that it disrupts the process it is drawn into.
How does it work?
HIV must convert its RNA genome into DNA using reverse transcriptase. Inside the cell, lamivudine is converted to an active form that the enzyme mistakes for real cytidine and incorporates into the growing DNA chain.
What happens then?
The chain stops. Natural building blocks carry an attachment point for the next one; lamivudine does not. The viral DNA is never completed and the infection cannot establish itself in that cell.
What is it used for?
HIV treatment, always in combination. It is also active against hepatitis B and is licensed to treat it, though tenofovir is generally preferred there because hepatitis B develops resistance to lamivudine relatively readily.
How is it different from emtricitabine?
Barely. The two are closely related cytidine analogues that work identically and are used interchangeably in most regimens. They should never be taken together, since the combination duplicates the same mechanism without adding anything.
Why has it lasted so long?
Because it is effective, extremely well tolerated, cheap, easy to combine and has almost no interactions. Newer drugs have displaced older agents in every other class, and lamivudine has simply remained useful.
What about its resistance barrier?
Low on its own. A single mutation, M184V, confers high-level resistance. That sounds worse than it is, because the same mutation weakens the virus and increases its susceptibility to some other drugs.
Does that affect how it is used?
Yes. Its resistance profile is assessed alongside its partner drugs rather than in isolation, and some regimens are designed deliberately to retain that mutation because of the fitness cost it imposes on the virus.
Can it be used in two-drug regimens?
Yes, and this is the significant recent development. Lamivudine with dolutegravir maintains suppression as effectively as three-drug regimens in suitable people, reducing long-term drug exposure.
Why is it never used alone?
Because a single mutation defeats it, so monotherapy would fail within weeks. Combination therapy is what makes the low barrier acceptable.
Does it treat anything else?
Hepatitis B, as above. It has no effect on any sexually transmitted infection and no preventive role for HIV, so regular screening remains necessary regardless.
How long has it been available?
Since the mid-1990s, giving it one of the longest safety records of any antiretroviral. That length of record is worth something in itself.
Is it available generically?
Widely, both alone and in combination, which has made it very inexpensive.
Where does it sit against the alternatives?
Interchangeable with emtricitabine in most situations. Which you take usually depends on which combination tablet suits the rest of your regimen rather than on any difference between them.
What happens when you start it?
Baseline blood tests first, covering kidney and liver function, lipids, viral load and CD4 count, plus hepatitis status and a resistance test. A follow-up appointment usually comes a few weeks later to check tolerability and early response.
Will you have to take it forever?
HIV treatment continues indefinitely, and what you take changes over the years. Being on lamivudine now does not commit you to it permanently, and most people are on something different a decade later as options improve.
Does it stop you passing HIV on?
Any regimen that achieves and sustains an undetectable viral load does, including this one. Once suppression is sustained, HIV is not transmitted sexually. That is a property of effective treatment rather than of lamivudine specifically.
What should you ask when it is first offered?
What this regimen requires daily, which side effects are common in the first month, what to do about a missed dose, and what the alternatives would be if it does not suit. Those four questions at the outset save a good deal later.